טוען...
Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines
Significant advances have been made in the design, discovery, and development of nanoparticles for cancer treatment in recent years. However, despite promising results in preclinical animal models, cancer nanomedicines often fail in clinical trials during phase II and phase III testing due to lack o...
שמור ב:
| הוצא לאור ב: | Adv Healthc Mater |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7473451/ https://ncbi.nlm.nih.gov/pubmed/32367687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202000110 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|